Pemivibart, a monoclonal antibody for preexposure prophylaxis for SARS-CoV-2, was recently authorized for emergency use by the FDA. The immunobridging data on which this EUA is based are presented.
The New England Journal of Medicine: Search Results in Allergy/Immunology
